Sodium-glucose co-transporter-2 (SGLT2) inhibitors have several beneficial effects in patients with type 2 diabetes, including glucose lowering, weight loss, blood pressure lowering, and a reduced risk of major adverse cardiovascular events.
In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether Myrbetriq/Betmiga (mirabegron),...
How is technology improving diagnosis and informing treatment decisions?
Eisai Co., Ltd. announced that it has obtained the manufacturing and marketing approval in Japan for its in-house discovered orexin...
Standard of care therapies for autosomal dominant polycystic kidney disease (ADPKD) may limit morbidity and mortality due to disease-related complications, but they do not delay disease progression.
This review article examines and summarises the differences in clinical findings of the most common anticoagulants when used in patients with chronic kidney disease.
Content: This review summarizes the evidence to date on optimum accelerated strategies for the rule-in and rule-out of AMI, using strategies focused on optimum use of troponin results.
This retrospective review compared the administration of four-factor prothrombin complex concentrate (4F-PCC) with a previous departmental protocol of three-factor prothrombin complex concentrate (3F-PCC) and activated factor VII (rVIIA).